Latest Breaking News On - Pembrolizumab as adjuvant monotherapy - Page 1 : comparemela.com

The European Commission has approved pembrolizumab as adjuvant monotherapy for the treatment of adult patients with non–small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

United statesGregory lubinieckiSolange petersMerck research laboratoriesEuropean commissionAmerican joint committee on cancerCentre hospitalier universitaire vaudoisEuropean unionAmerican joint committeePembrolizumab as adjuvant monotherapyPatients with non small cell lung cancerKeynote 091 trial